[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"juvenile-open-angle-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:juvenile-open-angle-glaucoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100650066","testing-a-reading-module-to-improve-reading-skills-and-quality-of-life-in-glaucoma-patients-100650066",false,"NCT07741812","Testing a Reading Module to Improve Reading Skills and Quality of Life in Glaucoma Patients","Evaluation of The Effectiveness Of Reading Rehabilitation Module On Reading Performance And Quality of Life In Patients With Glaucoma","Inclusion Criteria:\n\n* Age 18- 80 years old.\n* Confirmed diagnosis of bilateral Primary Open Angle Glaucoma (POAG),Primary Angle Closure Glaucoma (PACG), Normotensive Glaucoma (NTG) and Juvenile Open Angle Glaucoma (JOAG).\n* Bilateral visual acuity of 6\u002F60 and better.\n* Bilateral visual field defect more than 10degree from fixation.\n* Phakic without visually significant cataract.\n* Pseudophakic for more than 3 months prior to recruitment.\n* Literate patients.\n\nExclusion Criteria:\n\n* Ocular diseases other than glaucoma (e.g., age-related macula degeneration, diabetic retinopathy, moderate to severe cataract).\n* Other comorbidities that affect memory (e.g., stroke, cognitive disorders).\n* Cognitive disorders (e.g., diagnosed dementia or cognitive impairment).\n* Poorly controlled diabetes mellitus, hypertension and hyperlipidaemia.\n* Other media opacities.\n* History of previous intraocular surgery other than uncomplicated cataract within past 6 months.","ALL","18 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this interventional study is to test the effectiveness of reading rehabilitation module towards reading speed and error, and quality of life in glaucoma patients.The main questions it aims to answer are:\n\n1. Is there a significant difference in reading speed over a 6-month period between glaucoma patients who undergo a reading rehabilitation module and those who receive standard care?\n2. To what extent does the implementation of a reading rehabilitation module reduce the frequency of reading errors in glaucoma patients compared to a control group across baseline, 3-month, and 6-month follow-ups?\n3. How does a structured reading rehabilitation module influence the self-reported quality of life in glaucoma patients from baseline to 6 months when compared to those receiving standard care?\n\nParticipants will:\n\nPatients in interventional group will be instructed to practice the reading module for 20-30 minutes daily, minimum 3 days\u002Fweek, for 6 months.\n\nVisit the clinic once every 3 months for checkups and tests A logbook will be provided to record their practice sessions.\n\nWhile participants in control group will receive standard care, visit the clinic once every 3 months for checkups and tests.",[27,28,29,30],"Primary Open Angle Glaucoma (POAG)","Juvenile Open Angle Glaucoma","Normotensive Glaucoma","Primary Angle Closure Glaucoma",[32,33,34,35],"vision","low","reading rehabilitation","glaucoma","NOT_YET_RECRUITING","2026-08-07",{"date":39,"type":40},"2026-08-12","ACTUAL",{"date":42,"type":21},"2026-09-01",{"date":44,"type":21},"2027-12-31",{"name":46,"class":47},"Universiti Sains Malaysia","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100623423","phase-4-supplementary-kelulut-honey-therapy-in-juvenile-open-angle-glaucoma-effects-on-il-6-rnfl-and-dry-eye-100623423","NCT07396441","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.","HONEY-JOAG","Inclusion Criteria:\n\nJOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure\n\nExclusion Criteria:\n\nPatients with allergy to honey or honey-based products OCT signal less than 6\u002F10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.\n\nSepsis Compliance less than 75%.","15 Years","40 Years",{"count":60,"type":21},60,[62],"PHASE4","The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.",[28,65,66,67,68],"Dry Eye Disease (DED)","Interleukin 6","Retinal Nerve Fiber Layer Thickness","HbA1c Level","RECRUITING","2026-02-03",{"date":72,"type":40},"2026-02-09",{"date":74,"type":40},"2026-01-15",{"date":76,"type":21},"2026-06-30",{"name":46,"class":47},4]